The Molecular Identification and Antifungal Susceptibilities of Aspergillus Species Causing Otomycosis in Tochigi, Japan.
Antifungal susceptibility testing
Aspergillus species
Cryptic species
Molecular identification
Otomycosis
Journal
Mycopathologia
ISSN: 1573-0832
Titre abrégé: Mycopathologia
Pays: Netherlands
ID NLM: 7505689
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
13
04
2018
accepted:
24
09
2018
pubmed:
7
10
2018
medline:
19
3
2019
entrez:
7
10
2018
Statut:
ppublish
Résumé
Aspergillus species are the most common pathogenic fungi involved in otomycosis, an infection of the outer ear canal. In this study, we examined the incidence of Aspergillus infections and the antifungal susceptibilities of 30 Aspergillus species isolates from patients with otomycosis who visited Saiseikai Utsunomiya Hospital between August 2013 and July 2016. Based on the morphological test results, the strains were identified as Aspergillus niger sensu lato (20 strains), A. terreus sensu lato (7 strains), and A. fumigatus sensu lato (3 strains). In contrast, the molecular identifications based on analyzing the isolates' partial β-tubulin gene sequences revealed them to be A. niger sensu stricto (12 strains), A. tubingensis (8 strains), A. terreus sensu stricto (7 strains), and A. fumigatus sensu stricto (3 strains). The antifungal susceptibility test results indicated that strains of A. tubingensis and A. niger sensu stricto displayed lower susceptibilities to ravuconazole, compared with the other isolates. The Aspergillus strains from this study showed low minimum inhibitory concentrations toward the azole-based drugs efinaconazole, lanoconazole, and luliconazole. Therefore, these topical therapeutic agents may be effective for the treatment of otomycosis.
Identifiants
pubmed: 30291485
doi: 10.1007/s11046-018-0299-9
pii: 10.1007/s11046-018-0299-9
doi:
Substances chimiques
Antifungal Agents
0
Azoles
0
Tubulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13-21Références
J Clin Microbiol. 1999 Apr;37(4):920-4
pubmed: 10074502
Antimicrob Agents Chemother. 2002 Apr;46(4):1032-7
pubmed: 11897586
Nihon Ishinkin Gakkai Zasshi. 2003;44(4):277-83
pubmed: 14615794
J Infect Chemother. 2004 Aug;10(4):216-9
pubmed: 15365862
Antimicrob Agents Chemother. 2005 Dec;49(12):5136-8
pubmed: 16304186
Mycoses. 2007 Nov;50(6):447-50
pubmed: 17944704
Mycoses. 2008 Jan;51(1):67-70
pubmed: 18076598
Antimicrob Agents Chemother. 2008 Apr;52(4):1244-51
pubmed: 18212093
Antimicrob Agents Chemother. 2009 Oct;53(10):4514-7
pubmed: 19635955
J Clin Microbiol. 2009 Oct;47(10):3138-41
pubmed: 19675215
Mycopathologia. 2011 Oct;172(4):307-10
pubmed: 21499908
Mycoses. 2012 Jul;55(4):333-8
pubmed: 21895787
Mycoses. 2012 Mar;55(2):148-55
pubmed: 21929560
Mycoses. 2012 Sep;55(5):404-9
pubmed: 21999222
Mycopathologia. 2012 Aug;174(2):143-7
pubmed: 22359155
Ear Nose Throat J. 2012 Mar;91(3):114-21
pubmed: 22430336
Iran Red Crescent Med J. 2011 Dec;13(12):873-6
pubmed: 22737432
Antimicrob Agents Chemother. 2013 Apr;57(4):1610-6
pubmed: 23318803
Antimicrob Agents Chemother. 2013 Jul;57(7):3380-7
pubmed: 23669377
Pak J Med Sci. 2014 May;30(3):564-7
pubmed: 24948980
J Clin Microbiol. 2015 Feb;53(2):702-5
pubmed: 25502526
PLoS One. 2015 Mar 17;10(3):e0118997
pubmed: 25781896
Springerplus. 2014 Jan 10;3:19
pubmed: 26034655
Med Mycol. 2016 Jul 1;54(5):459-70
pubmed: 26773134
Microbiol Immunol. 2016 May;60(5):295-302
pubmed: 26969809
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6916-6919
pubmed: 27572389
J Fungi (Basel). 2017 May 05;3(2):null
pubmed: 29371538